Year archive

Bioversys N — 2026 filings

All 30 regulatory filings released by Bioversys N (BIOV) in 2026, sourced directly from the official regulator.

30 Filings

2026 Period

2026 filings (30)

Filing	Released	Lang
BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders Regulatory Filings	2026-04-30	English
BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders Regulatory Filings	2026-04-30	English
BioVersys completes BV100 Phase 1 clinical trial in China Regulatory Filings	2026-04-22	English
BioVersys completes BV100 Phase 1 clinical trial in China Regulatory Filings	2026-04-22	English
BioVersys Corporate Presentation April 2026 Investor Presentation	2026-04-22	English
BioVersys announces first patient first visit in HABP/VABP pivotal Phase 3 RIV-TARGET trial of BV100 Regulatory Filings	2026-04-16	English
BioVersys announces first patient first visit in HABP/VABP pivotal Phase 3 RIV-TARGET trial of BV100 Regulatory Filings	2026-04-16	English
BioVersys to present data on clinical and preclinical pipeline programs at ESCMID Global 2026 Regulatory Filings	2026-04-15	English
BioVersys to present data on clinical and preclinical pipeline programs at ESCMID Global 2026 Regulatory Filings	2026-04-15	English
Data published in Nature Communications highlights unique Mechanism of Action of Alpibectir in combination with Ethionamide (AlpE) Regulatory Filings	2026-04-13	English
Data published in Nature Communications highlights unique Mechanism of Action of Alpibectir in combination with Ethionamide (AlpE) Regulatory Filings	2026-04-13	English
BioVersys Issues Invitation to its 2026 Annual General Meeting of Shareholders Proxy Solicitation & Information Statement	2026-04-07	English
BioVersys Issues Invitation to its 2026 Annual General Meeting of Shareholders Proxy Solicitation & Information Statement	2026-04-07	English
BioVersys Appoints Anca Cighi as Head of Investor Relations and Communications Board/Management Information	2026-04-02	English
BioVersys Appoints Anca Cighi as Head of Investor Relations and Communications Board/Management Information	2026-04-02	English
BioVersys strengthens Ansamycin platform and NTM research through collaboration and license agreement with Hackensack Meridian Health Regulatory Filings	2026-03-31	English
BioVersys strengthens Ansamycin platform and NTM research through collaboration and license agreement with Hackensack Meridian Health Regulatory Filings	2026-03-31	English
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025 Earnings Release FY 2025	2026-03-18	English
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025 Earnings Release FY 2025	2026-03-18	English
BioVersys Annual Report 2025 Annual Report FY 2025	2026-03-18	English
BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start Regulatory Filings	2026-03-16	English
BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start Regulatory Filings	2026-03-16	English
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis Regulatory Filings	2026-03-12	English
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis Regulatory Filings	2026-03-12	English
BioVersys to Report its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call Report Publication Announcement	2026-03-05	English
BioVersys to Report its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call Report Publication Announcement	2026-03-05	English
BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy Regulatory Filings	2026-03-04	English
BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy Regulatory Filings	2026-03-04	English
BioVersys and partnersâ€™ Regulatory Filings	2026-02-19	English
BioVersys and partners phase 2a tuberculosis trial results published in New England Journal of Medicine Regulatory Filings	2026-02-19	English